Neutropénie fébrile au cours des cancers pulmonaires

Febrile neutropenia is a major complication of chemotherapy treatments in patients with lung cancer because of its morbidity and mortality. Neutropenia risk assessment should be carried out before each chemotherapy cycle taking into account the factors related to chemotherapy as well as those of the patient. The management of febrile neutropenia should be done urgently most often in hospitalization with clinical, biological and radiological evaluation. The frequency and potential severity of a bacterial infection requires early and empiric antibiotic treatment. Clinical and biological evolution determines the duration of the antibiotic therapy. Antibiotherapy prophylaxis is not recommended and the use of GCSF in primary prophylaxis is reserved for patients at high risk of febrile neutropenia (>20%).